Callisto, M.D. Anderson to develop Degrasyn anti-cancer agents

By Elaine Rigoli

Tampa, Fla., May 10 - Callisto Pharmaceuticals, Inc. said Wednesday it has executed a sponsored research agreement with the University of Texas M.D. Anderson Cancer Center to support and accelerate development of the company's Degrasyn class of cancer-fighting compounds.

The two-year agreement will support intensive laboratory work by a team of research scientists at M.D. Anderson, who will focus on the novel synthesis and molecular modeling of Degrasyn compounds, according to a news release.

Callisto recently licensed the Degrasyn class of compounds, formerly referred to as tyrphostins, from the M.D. Anderson Cancer Center.

The anti-cancer activity of Degrasyns relates to their ability to selectively degrade key proteins that are involved in tumor growth and survival.

The University of Texas M.D. Anderson Cancer Center is a research and clinical center devoted to the treatment of cancer.

New York-based Callisto is a biopharmaceutical company focused on the development of new drugs to treat various forms of cancer and other serious afflictions.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.